United States: FDA Goes Purple On Biologics And Biosimilars: Composes A Variation On A Theme Of Orange

Since the early 1980s, the pharmaceutical industry, as well as the pharmacy boards that control substitution at the state level, have relied on FDA's Orange Book to determine which drugs are not only approved, but also those generic versions that are therapeutically equivalent to the brand name product and may be substituted at the pharmacy level. With the passage in 2010 of the Biologics Price Competition and Innovation Act (BPCIA), the potential for the development of lower cost biosimilar versions of often very expensive brand name biologics products has been emerging. Indeed, the first biosimilar applications submitted to FDA were recently announced in July and August 2014 by both Sandoz and Celltrion. However, to date, there was no FDA list similar to the Orange Book of approved biologics that could serve as the reference product required for a biosimilar application. On September 9, 2014, FDA filled that void by announcing the creation of the Purple Book, which lists approved innovator biologic applications, and also includes a column to indicate not only when the biologic was first approved, but also a column in which the date that the 12-year exclusivity period mandated by the BPCIA will (or has) expired.

Avid readers of the Orange Book, however, will find the Purple Book very scanty in comparison. First, and not surprising, there are no approved biosimilars listed, as only two have been submitted and both of those in the last few months--the Sandoz and Celltrion applications as referred to above. Second, while the approved biologics are listed in alphabetical order by their non-proprietary names, most of the information regarding not only the date of first approval, but also the end of the 12-year exclusivity period has not yet been completed in the initial iterations of the Purple Book. FDA, however, cautions that the absence of the information should not be construed as indicating that the approved BLA in question is not entitled to exclusivity. The agency also made clear that it will be updating the list as necessary going forward.

The Purple Book has basically two chapters, referred to as lists. The first covers biologics that have been licensed through the Center for Drug Evaluation and Research (CDER), which, since June 2003, has had the responsibility of reviewing the vast majority of therapeutic protein products. The second chapter, or list, covers those BLAs that were licensed by the Center for Biologics Evaluation and Research (CBER). After June 2003, CBER retained jurisdiction over BLAs for vaccines, blood products, gene therapy, cell therapy, and several other types of product (click here for more information on the 2003 transfer to BLAs to CDER).

With respect to the yet-to-be launched birth of a biosimilar, the Purple Book does include a column to indicate whether the product is Interchangeable, to be indicated by a capital "I," or a biosimilar that has not been awarded interchangeability, to be noted by a capital "B."

The use of the "I" to denote an interchangeable biologic is consistent with comments this author previously made in a presentation in February 2014 to the 2nd Annual World Biosimilars and Biobetters Congress in Philadelphia. In a presentation on U.S. regulation of biosimilars, I advocated that it's time to start thinking about a biologic that FDA approves under the BPCIA as interchangeable to an innovator reference product without using the term "biosimilar." Rather, I asserted, the appropriate term should be to simply call them Interchangeable biologics, or "Interchangeables."

My nomenclature change suggestion reflects the key distinction that exists under the BPCIA between different types of biologics being developed under the BPCIA's abbreviated pathway. Initially, applicants will, according to FDA prior guidance, only be able to secure a finding of biosimilarity. Thereafter, an applicant, even with a licensed biosimilar, would have to do additional testing to show that its product is interchangeable. While we await FDA guidance on the details of how to prove interchangeability, if an applicant were successful in proving interchangeability, then, in my view, it would be appropriate to no longer refer to that product as a biosimilar, but as an Interchangeable to reflect the fact that FDA would have concluded, in so approving it, that the product can be used freely in place of the reference biologic product that formed the basis for the interchangeable application under § 351(k) of the Public Health Service Act.

Returning to the Purple Book, FDA appears to agree with this difference in terminology by adopting the "I" for an Interchangeable application approved under Section 351(k), as opposed to the "B" for a Biosimilar application that was approved without a finding of interchangeability.

Devotees of the Orange Book will not, however, find in the Purple Book the detailed information on patents that is required under the 1984 Drug Price Competition and Patent Term Restoration Act ("Hatch-Waxman"), for the simple reason that, unlike with Hatch-Waxman, the BPCIA's patent provisions operate outside of any substantive interaction with the FDA approval process for biosimilars. While this certainly does not signify that patents are not a key issue in the development of biosimilars, it does mean that a biosimilar application can go forward at FDA without the agency having to be concerned with the status of any pending patent litigation. Rather, the only possible FDA bar to approval of an otherwise complete and robust biosimilar application might be the terms of any exclusivity that the innovator product enjoys.

On the patent litigation side, however, it is important to keep in mind that FDA's acceptance of the biosimilar application filed by Sandoz and, ultimately when Celltrion's is accepted for filing*will serve as the trigger for patent litigation deadlines in the BPCIA. Within 20 days after FDA acceptance, the 351(k) applicant must provide a copy of the application and manufacturing information to the reference product sponsor. This, in turn, triggers the reference product sponsor's 60 day deadline to provide a list of patents to the biosimilar applicant. After two more 60-day periods for additional exchanges of the bases for a patent challenge, and the bases for patent enforcement and following a brief period of further negotiations, the reference product sponsor can file suit against the biosimilar applicant. Therefore, we anticipate the first biosimilar patent litigations under the BPCIA to be initiated in March or April of 2015.

Also missing from the Purple Book are those biologics that, for historical reasons, such as human growth hormone and recombinant insulin products, were approved not under the BLA provisions of the Public Health Service Act, but under the new drug application (NDA) provisions of the Federal Food, Drug, and Cosmetic Act (FFDCA). Under the BPCIA, a biosimilar application technically cannot be filed for a brand name biologic product that is approved under the NDA process. Rather, someone seeking to market a lower cost biologic based on showing similarity to an innovator biologic approved under an NDA also must submit an NDA, most likely under § 505(b)(2) of the FFDCA. Indeed, one of the first products approved in the United States that is in the nature of a "biosimilar" was secured under the 505(b)(2) NDA process in June 2006, when Sandoz secured approval of a version of Pfizer's Genotropin® via the 505(b)(2) process.

The launch of the Purple Book represents another key step forward in FDA's iterative approach to the regulation of biosimilars under the BPCIA. While, given the key differences between the regulatory regimes established by the BPCIA and Hatch-Waxman, the new reference will not spur as intense scrutiny as the Orange Book does for the small molecule generic drug approval process, its emergence further portends the day when a line will be added to the Purple Book announcing the first approval of a biosimilar under the BPCIA.

So stay tuned.

* Note: the Celltrion press release on its 351(k) application did not affirmatively state that FDA had accepted the Celltrion 351(k) application for filing. Rather, the company stated that it had "completed the filing procedure." Thus, we can not say for sure if Celltrion's application has reached that level of processing at FDA that it has been accepted for filing or is still in the initial review stage to see if it is sufficiently complete so as to be accepted for filing.

Disclaimer: This Alert has been prepared and published for informational purposes only and is not offered, nor should be construed, as legal advice. For more information, please see the firm's full disclaimer.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions